Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) has been given a $8.00 price target by stock analysts at Maxim Group in a report issued on Friday. The firm currently has a a “buy” rating on the stock. Maxim Group’s price objective would indicate a potential upside of 67.71% from the stock’s previous close.

Oculus Innovative Sciences (NASDAQ:OCLS) opened at 4.77 on Friday. The stock’s market cap is $20.03 million. Oculus Innovative Sciences has a 12-month low of $3.57 and a 12-month high of $7.15. The firm has a 50-day moving average of $4.26 and a 200-day moving average of $4.39.

About Oculus Innovative Sciences

Oculus Innovative Sciences, Inc is a specialty pharmaceutical company, which focuses on identifying, developing and commercializing therapies to manage the lives of patients with dermatologic diseases or conditions. The Company’s products treat certain topical skin diseases, including acne, atopic dermatitis, scarring, infections, itch, pain and inflammatory responses.

5 Day Chart for NASDAQ:OCLS

Receive News & Stock Ratings for Oculus Innovative Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculus Innovative Sciences Inc. and related stocks with our FREE daily email newsletter.